Vantage Point: Marketing Support for Clinical Trials

Richard Vanderveer
Richard Vanderveer

In 2014, it is increasingly important for pharmaceutical companies to provide robust marketing support for their clinical trials.  While in the “good old days,” companies would often simply put studies into the field and hope for the best, it is increasingly clear that such a laissez-faire approach is far from optimal. It is estimated that 70% of clinical trials encounter one or more significant delays, with the average daily cost of such a delay being $1 million!

Companies that successfully avoid such pitfalls do so by being proactive. They prepare for the launch of a clinical trial exactly as they would prepare for the launch of a new product.  As the trial progresses, they follow the edict that “You must continuously sell your clinical trial to every one of its stakeholders!”

Specialized marketing research is increasingly used to support these marketing efforts. Stakeholders studied can be viewed as a “cascade” that flows downward from the company's own headquarters clinical team. These team members are typically multitasking, and trouble awaits a clinical study that cannot maintain their attention.  Clinical investigators, clinical research associates and referring physicians are also surveyed to find potential roadblocks. Patient recruitment materials are carefully scrutinized.

Clinical trials increasingly require such rigor.  Half of the 139 drugs approved by the FDA since 2009 were for rare diseases or cancer. Thus, certain specialties (e.g., oncologists) and rare-disease patients alike are besieged by avalanches of clinical trial invitations.

We are witnessing the emergence of a new way in which experienced marketers and marketing researchers can apply their skills. I am excited by these opportunities, and hope you are as well.


Richard Vanderveer is chief solutions officer, rbv3.

You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.